Jiangsu Hengrui Medicine Co., Ltd
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1970-01-01
- Employees
- -
- Market Cap
- $38.9B
A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors
- First Posted Date
- 2020-06-24
- Last Posted Date
- 2023-07-21
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 226
- Registration Number
- NCT04446260
- Locations
- 🇺🇸
Gabrail Cancer Center, Canton, Ohio, United States
🇰🇷Seoul National University Hospital, Seoul, Korea, Republic of
🇦🇺Macquarie University Hospital, Macquarie, New South Wales, Australia
A Safety and Efficacy Study of SHR-1702 Monotherapy in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
- First Posted Date
- 2020-06-23
- Last Posted Date
- 2023-08-24
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 31
- Registration Number
- NCT04443751
- Locations
- 🇨🇳
Blood disease hospital of Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
Effect of Rifampicin on the Pharmacokinetics of SHR6390 in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2020-06-19
- Last Posted Date
- 2021-10-18
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT04439578
- Locations
- 🇨🇳
Zhejiang provincial people's hospital, Hangzhou, Zhejiang, China
A Multiple Dose Study to Evaluate the Effect of SHR-1222 Injection in Postmenopausal Osteoporosis Patients
- First Posted Date
- 2020-06-17
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 107
- Registration Number
- NCT04435158
- Locations
- 🇨🇳
2nd Xiangya Hospital , Chinese Academy of Medical Sciences, Changsha, Hunan, China
A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Resectable Pancreatic Cancer
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2020-12-31
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 74
- Registration Number
- NCT04425876
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
Study of Camrelizumab (SHR-1210) in Combination With Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2021-09-16
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 396
- Registration Number
- NCT04426955
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
A Pharmacokinetic Interaction Study Between Apatinib and Rosuvastatin or Metformin in Solid Tumor Subjects.
- Conditions
- Interventions
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2022-07-26
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 19
- Registration Number
- NCT04428086
- Locations
- 🇨🇳
The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
Effect of Itraconazole on the Pharmacokinetics of SHR6390 in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2020-06-09
- Last Posted Date
- 2021-10-18
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT04423601
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
The Pharmacokinetic(PK)/Pharmacodynamics(PD) Study of SHR7280 Tablets in Premenopausal Subjects With Endometriosis.
- First Posted Date
- 2020-06-05
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 179
- Registration Number
- NCT04417972
- Locations
- 🇨🇳
Peking University Third Hospital, Peking, Beijing, China
A Study to Evaluate the Pharmacokinetics of Apatinib in Subjects With Impaired Renal Function
- Conditions
- Interventions
- First Posted Date
- 2020-06-04
- Last Posted Date
- 2020-06-04
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT04414852